These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 20695978

  • 1. Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice.
    Eckly A, Rinckel JY, Laeuffer P, Cazenave JP, Lanza F, Gachet C, Léon C.
    J Thromb Haemost; 2010 Oct; 8(10):2243-51. PubMed ID: 20695978
    [Abstract] [Full Text] [Related]

  • 2. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation.
    Eckly A, Strassel C, Freund M, Cazenave JP, Lanza F, Gachet C, Léon C.
    Blood; 2009 Apr 02; 113(14):3182-9. PubMed ID: 18984861
    [Abstract] [Full Text] [Related]

  • 3. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.
    Pal K, Nowak R, Billington N, Liu R, Ghosh A, Sellers JR, Fowler VM.
    Blood; 2020 May 21; 135(21):1887-1898. PubMed ID: 32315395
    [Abstract] [Full Text] [Related]

  • 4. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition.
    Chen Y, Boukour S, Milloud R, Favier R, Saposnik B, Schlegel N, Nurden A, Raslova H, Vainchenker W, Balland M, Nurden P, Debili N.
    J Thromb Haemost; 2013 Dec 21; 11(12):2163-75. PubMed ID: 24165359
    [Abstract] [Full Text] [Related]

  • 5. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation.
    Pecci A, Malara A, Badalucco S, Bozzi V, Torti M, Balduini CL, Balduini A.
    Thromb Haemost; 2009 Jul 21; 102(1):90-6. PubMed ID: 19572073
    [Abstract] [Full Text] [Related]

  • 6. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion.
    Léon C, Eckly A, Hechler B, Aleil B, Freund M, Ravanat C, Jourdain M, Nonne C, Weber J, Tiedt R, Gratacap MP, Severin S, Cazenave JP, Lanza F, Skoda R, Gachet C.
    Blood; 2007 Nov 01; 110(9):3183-91. PubMed ID: 17664350
    [Abstract] [Full Text] [Related]

  • 7. Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome.
    Strassel C, Eckly A, Léon C, Petitjean C, Freund M, Cazenave JP, Gachet C, Lanza F.
    Haematologica; 2009 Jun 01; 94(6):800-10. PubMed ID: 19377075
    [Abstract] [Full Text] [Related]

  • 8. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets.
    Pertuy F, Eckly A, Weber J, Proamer F, Rinckel JY, Lanza F, Gachet C, Léon C.
    Blood; 2014 Feb 20; 123(8):1261-9. PubMed ID: 24243973
    [Abstract] [Full Text] [Related]

  • 9. Importance of environmental stiffness for megakaryocyte differentiation and proplatelet formation.
    Aguilar A, Pertuy F, Eckly A, Strassel C, Collin D, Gachet C, Lanza F, Léon C.
    Blood; 2016 Oct 20; 128(16):2022-2032. PubMed ID: 27503502
    [Abstract] [Full Text] [Related]

  • 10. Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes.
    Balduini A, Pallotta I, Malara A, Lova P, Pecci A, Viarengo G, Balduini CL, Torti M.
    J Thromb Haemost; 2008 Nov 20; 6(11):1900-7. PubMed ID: 18752571
    [Abstract] [Full Text] [Related]

  • 11. Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.
    Zhang Y, Conti MA, Malide D, Dong F, Wang A, Shmist YA, Liu C, Zerfas P, Daniels MP, Chan CC, Kozin E, Kachar B, Kelley MJ, Kopp JB, Adelstein RS.
    Blood; 2012 Jan 05; 119(1):238-50. PubMed ID: 21908426
    [Abstract] [Full Text] [Related]

  • 12. Establishment of mouse model of MYH9 disorders: heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability.
    Suzuki N, Kunishima S, Ikejiri M, Maruyama S, Sone M, Takagi A, Ikawa M, Okabe M, Kojima T, Saito H, Naoe T, Matsushita T.
    PLoS One; 2013 Jan 05; 8(8):e71187. PubMed ID: 23976996
    [Abstract] [Full Text] [Related]

  • 13. Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD.
    Léon C, Evert K, Dombrowski F, Pertuy F, Eckly A, Laeuffer P, Gachet C, Greinacher A.
    Blood; 2012 Apr 05; 119(14):3333-41. PubMed ID: 22234693
    [Abstract] [Full Text] [Related]

  • 14. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway.
    Chen Z, Naveiras O, Balduini A, Mammoto A, Conti MA, Adelstein RS, Ingber D, Daley GQ, Shivdasani RA.
    Blood; 2007 Jul 01; 110(1):171-9. PubMed ID: 17392504
    [Abstract] [Full Text] [Related]

  • 15. Myosin-II repression favors pre/proplatelets but shear activation generates platelets and fails in macrothrombocytopenia.
    Spinler KR, Shin JW, Lambert MP, Discher DE.
    Blood; 2015 Jan 15; 125(3):525-33. PubMed ID: 25395423
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Actin inhibition increases megakaryocyte proplatelet formation through an apoptosis-dependent mechanism.
    Avanzi MP, Izak M, Oluwadara OE, Mitchell WB.
    PLoS One; 2015 Jan 15; 10(4):e0125057. PubMed ID: 25875470
    [Abstract] [Full Text] [Related]

  • 18. Characterization of megakaryocyte development in the native bone marrow environment.
    Eckly A, Strassel C, Cazenave JP, Lanza F, Léon C, Gachet C.
    Methods Mol Biol; 2012 Jan 15; 788():175-92. PubMed ID: 22130708
    [Abstract] [Full Text] [Related]

  • 19. Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes.
    Lecine P, Villeval JL, Vyas P, Swencki B, Xu Y, Shivdasani RA.
    Blood; 1998 Sep 01; 92(5):1608-16. PubMed ID: 9716588
    [Abstract] [Full Text] [Related]

  • 20. Action of thrombopoietin at the megakaryocyte progenitor level is critical for the subsequent proplatelet production.
    Horie K, Miyazaki H, Hagiwara T, Tahara E, Matsumoto A, Kadoya T, Ogami K, Kato T.
    Exp Hematol; 1997 Feb 01; 25(2):169-76. PubMed ID: 9015217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.